Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Muvalaplin - Eli Lilly and Company

Next Previous
Drug Profile

Muvalaplin - Eli Lilly and Company

Alternative Names: LY-3473329

Latest Information Update: 12 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperlipidaemics; Benzylamines; Propionic acids; Pyrrolidines; Small molecules
  • Mechanism of Action Lipoprotein A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipidaemia

Most Recent Events

  • 02 Sep 2025 Phase-III clinical trials in Hyperlipidaemia in Argentina, Austria, Belgium, Canada, Czech Republic, Denmark, France, Greece, India, Italy, Mexico, Poland, Romania, Slovakia, South Korea, Spain, Taiwan, United Kingdom (PO) (NCT07157774)
  • 02 Sep 2025 Phase-III clinical trials in Hyperlipidaemia in Brazil, Australia, Japan, China, Germany, Hungary, Netherlands, USA (PO) (NCT07157774)
  • 18 Nov 2024 Efficacy and adverse event data from the phase II KRAKEN trial in Hyperlipidaemia released by Eli Lilly and Company

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top